Levosulpiride Sr Pellets 50% W/W Pellets

What are Levosulpiride Sr Pellets 50% W/W Pellets?

Levosulpiride Sr Pellets 50% W/W Pellets are a pharmaceutical pellet formulation containing levosulpiride at a stated drug loading of 50% w/w. The SR designation indicates a sustained-release formulation characteristic, which should be verified against the product specification. These pellets may be intended for further pharmaceutical processing into suitable dosage forms, subject to confirmation of their composition, release profile and intended application.

Uses / Applications

Levosulpiride SR pellets may be used as pharmaceutical intermediates for the development and manufacture of suitable dosage forms, provided their specifications support the intended application.

Potential applications include:

• Formulation development for levosulpiride-containing medicines.

• Incorporation into suitable oral dosage forms where technically appropriate.

• Pharmaceutical manufacturing processes requiring a specified levosulpiride drug loading.

• Further processing in accordance with validated formulation procedures.

Therapeutic context: Levosulpiride is used in certain countries in medicines for gastrointestinal motility disorders and other approved indications. The specific indications depend on the finished medicinal product and local prescribing information. These uses should not be interpreted as confirmation that the supplied pellets are suitable for direct administration.

6. Benefits

Potential formulation-related considerations include:

• A stated levosulpiride drug loading of 50% w/w.

• A pellet-based presentation for pharmaceutical formulation development.

• An SR designation that identifies a sustained-release formulation characteristic requiring technical verification.

• Potential suitability for further pharmaceutical processing, subject to the applicable specifications.

Drug-loading uniformity, release performance, particle-size distribution, stability and compatibility with manufacturing processes must be confirmed through product-specific documentation and testing.

7. Side Effects

If the pellets are pharmaceutical intermediates, patient-level adverse effects cannot be determined from the pellet dosage form alone.

Finished medicines containing levosulpiride may cause adverse effects depending on the dose, formulation, duration of use and individual patient factors. Potential effects can include:

• Drowsiness or dizziness.

• Gastrointestinal disturbances.

• Elevated prolactin levels, which may cause hormonal effects.

• Movement-related adverse effects in some patients.

The specific risks and their frequency must be checked against the approved prescribing information for the final medicinal product. These pellets should not be assumed suitable for direct patient administration.

8. How Does It Work?

Formulation mechanism: The SR designation suggests a sustained-release formulation intended to influence the rate at which levosulpiride is released. The precise release mechanism, coating composition and performance characteristics have not been supplied and should be confirmed through the technical documentation.

Pharmacological mechanism: Levosulpiride is a substituted benzamide compound with dopamine D2-receptor antagonist activity. Its pharmacological effects depend on the therapeutic application and the characteristics of the finished medicinal product.

The pharmacological mechanism does not, by itself, establish the release performance of the supplied pellets.

9. Dosage Guidelines / Processing Instructions

For pharmaceutical intermediates, incorporation quantities depend on the verified drug loading, target dosage strength, final formulation and validated manufacturing process.

• Confirm the stated 50% w/w drug loading against the product specification.

• Verify the intended sustained-release profile before formulation.

• Establish incorporation quantities through appropriate formulation calculations and quality testing.

• Follow the supplier’s technical documentation and validated manufacturing procedures.

No processing quantities, mixing times, temperatures or patient dosing instructions should be inferred from the product name alone.

10. When Not to Use

For pharmaceutical intermediates, suitability depends on the intended application and applicable quality requirements.

• Do not use material that fails the receiving manufacturer’s approved specifications.

• Do not use material with damaged packaging or suspected contamination without appropriate assessment.

• Do not incorporate the pellets into a finished medicine until identity, drug loading and release characteristics have been verified.

Contraindications for patients should be assessed against the approved prescribing information for the final levosulpiride medicinal product.

11. Drug / Product Interactions

For pharmaceutical intermediates, formulation compatibility must be distinguished from clinical drug interactions.

• Compatibility with other active ingredients and excipients requires formulation assessment.

• Manufacturing conditions should be evaluated for their effects on the active ingredient and release characteristics.

• Sustained-release performance should be evaluated using appropriate product-specific testing.

• Clinical interactions involving levosulpiride should be assessed using the approved information for the finished medicinal product.

No specific excipient compatibility or manufacturing-process compatibility is confirmed by the product name alone.

12. Safety Advice

• Handle the pellets according to the applicable safety data sheet and technical documentation.

• Follow the receiving manufacturer’s material-handling and quality-control procedures.

• Apply appropriate precautions based on the active ingredient and identified occupational hazards.

• Maintain batch identification and material traceability.

• Request relevant technical and safety documentation before establishing handling procedures.

13. General Instructions

• Verify the product name and stated 50% w/w drug loading.

• Check batch identification and applicable manufacturing, expiry or retest details.

• Inspect the packaging for damage or possible contamination.

• Review the certificate of analysis and technical data sheet, where available.

• Confirm the release profile and intended application before formulation.

• Maintain appropriate quality-control and material traceability records.

14. Special Dietary / Lifestyle Tips

Dietary and lifestyle advice is generally not applicable to pharmaceutical intermediates. Patient-specific advice depends on the final levosulpiride-containing medicine and its approved prescribing information.

15. Comparison with Other Formulations

This comparison describes general formulation differences and does not establish superiority or confirmed performance for the supplied product.

16. Precautions & Warnings

• Confirm the drug-loading strength and release profile against the supplier’s documentation.

• Do not assume a specific coating or release technology without supporting specifications.

• Follow the applicable storage, handling and manufacturing requirements.

• Verify formulation compatibility before combining the pellets with other materials.

• Ensure the material meets the receiving manufacturer’s quality requirements before use.

17. Can I Use It With Other Medicines or Ingredients?

Compatibility with other active ingredients and excipients must be established through formulation development and appropriate technical assessment. The sustained-release characteristics, if confirmed, must be considered when evaluating the intended finished dosage form.

For clinical use, concomitant medicines should be assessed according to the approved information for the final levosulpiride-containing product.

18. Storage

Store according to the manufacturer’s approved product specifications and technical documentation. Refer to the product packaging or applicable technical data sheet for the required storage conditions.

19. Frequently Asked Questions (FAQs)

1. What are Levosulpiride SR Pellets 50% W/W Pellets?

They are a levosulpiride-based pharmaceutical pellet formulation with a stated drug loading of 50% w/w. Their release characteristics and intended application should be confirmed through the supplier’s documentation.

2. What is the active ingredient?

The stated active ingredient is levosulpiride.

3. What does 50% W/W mean?

It denotes a stated drug-loading proportion of 50% by weight. The exact basis and specification should be verified with the supplier.

4. What does SR mean in the product name?

SR generally stands for sustained release. The specific release profile and performance of this product require confirmation through its technical specification.

5. Are these pellets intended for direct administration?

Direct administration suitability has not been confirmed. Their intended use and compatibility with a finished dosage form must be established from the product documentation.

6. What packing options are available?

Packing details are available on request. Specific packaging configurations should be confirmed with the supplier.

7. Is technical documentation available?

The technical data sheet is available upon request. The availability of a certificate of analysis and other quality documents should be confirmed separately.

8. Can Kelar Pharmachem India support pharmaceutical export requirements?

Kelar Pharmachem India is a pharmaceutical sourcing and export company supporting international pharmaceutical supply requirements. Product specifications, documentation and destination-market requirements should be confirmed for each enquiry.